The Clinical Trials in Alzheimer’s Disease congress took place last week in Madrid, with BioArctic co-founder, Lars Lannfelt, receiving the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. His research on the amyloid beta protein eventually led to the development of lecanemab. In a statement, he said: "This field of research is in the midst of a paradigm shift driven by the development of treatments such as lecanemab, which has demonstrated meaningful benefits to patients in the large phase III trial Clarity AD using gold standard endpoints. Coupled with the introduction of new diagnostic methods, I am convinced that within a number of years, we will not only be able to slow the progression of the disease, but eventually also stop the disease process entirely."

Incidentally, when I first started out in my career as a science writer, one of my first stories focused on amyloid plaques and Alzheimer’s so it’s incredible to see the progress that has been made since then.

As part of a special feature focused on the future of the biopharma industry, The Medicine Maker has been asking people for their views on the future of medicine. Alzheimer’s disease is a topic that has been mentioned frequently in submissions. You can read the opinions here.

What are your thoughts on the future of Alzheimer’s disease drug development and treatment? Let me know: stephanie.vine@texerepublishing.com